Human immunodeficiency virus reservoir might be actively eradicated as residual malignant cells by cytotoxic chemotherapy

被引:6
作者
Yang, Q [1 ]
机构
[1] SAIC Frederick Inc, Natl Canc Inst, Lab Antiviral Drug Mech, Frederick, MD 21702 USA
关键词
D O I
10.1016/j.mehy.2003.10.012
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
A unique characteristic of human immunodeficiency virus (HIV) infection is that the virus must incorporate its cDNA into the host genomic DNA for replication. Once the virus gets into the host genome and becomes a part of the host genetic materials, elimination of the virus without killing the infected cells is virtually impossible. The use of highly active antiretroviral therapy (HAART) can result in a substantial decline in viremia. However, HAART does not eradicate HIV. The progressive HIV infection wilt unavoidably rebound after a cessation of the treatment. Searching for a new combination therapeutic strategy with cytotoxic agents that eliminate or significantly reduce the HIV reservoir is a potential way for better control of the disease. Theoretically, the HIV reservoir can be gradually eradicated by long-term use of certain antimetabolic cytotoxic drugs coupled with proper activation of latently infected cells, if viral replication is completely blocked by antiretroviral chemotherapy to protect uninfected, susceptible cells. (C) 2003 Elsevier Ltd. All rights reserved.
引用
收藏
页码:358 / 363
页数:6
相关论文
共 39 条
[1]   THE CYTOTOXICITY OF THIOGUANINE VS MERCAPTOPURINE IN ACUTE LYMPHOBLASTIC-LEUKEMIA [J].
ADAMSON, PC ;
POPLACK, DG ;
BALIS, FM .
LEUKEMIA RESEARCH, 1994, 18 (11) :805-810
[2]   INHIBITION OF HUMAN IMMUNODEFICIENCY VIRUS IN EARLY INFECTED AND CHRONICALLY INFECTED-CELLS BY ANTISENSE OLIGODEOXYNUCLEOTIDES AND THEIR PHOSPHOROTHIOATE ANALOGS [J].
AGRAWAL, S ;
IKEUCHI, T ;
SUN, D ;
SARIN, PS ;
KONOPKA, A ;
MAIZEL, J ;
ZAMECNIK, PC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (20) :7790-7794
[3]   Addition of cyclophosphamide to antiretroviral therapy does not diminish the cellular reservoir in HIV-infected persons [J].
Bartlett, JA ;
Miralles, GD ;
Sevin, AD ;
Silberman, M ;
Pruitt, SK ;
Ottinger, J ;
Gryszowska, V ;
Fiscus, SA ;
Bucy, RP .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2002, 18 (08) :535-543
[4]   AIDS - Re-emergence of HIV after stopping therapy [J].
Chun, TW ;
Davey, RT ;
Engel, D ;
Lane, HC ;
Fauci, AS .
NATURE, 1999, 401 (6756) :874-875
[5]   Quantification of latent tissue reservoirs and total body viral load in HIV-1 Infection [J].
Chun, TW ;
Carruth, L ;
Finzi, D ;
Shen, XF ;
DiGiuseppe, JA ;
Taylor, H ;
Hermankova, M ;
Chadwick, K ;
Margolick, J ;
Quinn, TC ;
Kuo, YH ;
Brookmeyer, R ;
Zeiger, MA ;
BarditchCrovo, P ;
Siliciano, RF .
NATURE, 1997, 387 (6629) :183-188
[6]   Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy [J].
Chun, TW ;
Engel, D ;
Mizell, SB ;
Hallahan, CW ;
Fischette, M ;
Park, S ;
Davey, RT ;
Dybul, M ;
Kovacs, JA ;
Metcalf, JA ;
Mican, JM ;
Berrey, MM ;
Corey, L ;
Lane, HC ;
Fauci, AS .
NATURE MEDICINE, 1999, 5 (06) :651-655
[7]   Transmission of drug-resistant strains of HIV-1: unfortunate, but inevitable [J].
Cohen, OJ ;
Fauci, AS .
LANCET, 1999, 354 (9180) :697-698
[8]  
CONTU L, 1993, BONE MARROW TRANSPL, V12, P669
[9]   Monoclonal antibody therapy for lymphoma -: An update [J].
Dillman, RO .
CANCER PRACTICE, 2001, 9 (02) :71-80
[10]   THE PURINE PATH TO CHEMOTHERAPY [J].
ELION, GB .
SCIENCE, 1989, 244 (4900) :41-47